ARIAD Pharmaceuticals Inc. (ARIA) Stock Quote

Detailed Quote for ARIAD Pharmaceuticals Inc. (ARIA)

After Hours: $ 14.64

-0.015 (-0.10%)

Volume: 1.45 k

5:35 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

February 6, 2012

Close: 15.98

52 Week Low

March 15, 2011

Close: 5.52

Today

Last Price
14.655

Change $
0.305

Change %
2.04%

Tick
N/A

Bid
N/A

Bid Size
0

Ask
N/A

Ask Size
0

Open
14.88

High
14.97

Low
14.42

Prev Close
14.96

Last Trade
2/10/12

Volume
3.34 m

52 Wk Hi
15.98

52 Wk Low
5.52

Market Cap
2.31 b

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
157,599,000

EPS (TTM)
-0.85

PE Ratio
N/A

close Exchange Information Listed On Nasdaq Global Select (NGS) Exchange
NGS

News and Media for ARIAD Pharmaceuticals Inc. (ARIA)

Sector News | Topic News

News for ARIA

Thu, Feb 02, 2012

7:35 AM

ARIAD to Present at Upcoming Investor Conferences - Business Wire

Wed, Jan 04, 2012

7:35 AM

ARIAD to Present at the 30th Annual J.P. Morgan Healthcare Conference - Business Wire

Tue, Jan 03, 2012

7:35 AM

ARIAD to Trade on the NASDAQ Global Select Market - Business Wire

Tue, Dec 20, 2011

4:15 PM

ARIAD Announces Completion of Public Offering - Business Wire

Fri, Dec 16, 2011

9:20 AM

ARIAD Announces Underwriters' Exercise of Over-Allotment Option - Business Wire

Thu, Dec 15, 2011

9:25 AM

ARIAD Announces Pricing of Public Offering of Common Stock - Business Wire

Wed, Dec 14, 2011

4:16 PM

ARIAD Announces Proposed Public Offering of Common Stock - Business Wire

Sun, Dec 11, 2011

7:30 PM

ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor - Business Wire

Tue, Dec 06, 2011

7:35 AM

ARIAD to Present at the Oppenheimer 22nd Annual Healthcare Conference - Business Wire

Mon, Dec 05, 2011

7:35 AM

ARIAD Announces Investor Meeting and Webcast at American Society of Hematology Meeting - Business Wire

Mon, Nov 28, 2011

7:35 AM

ARIAD to Present at the 2011 Deutsche Bank BioFEST - Business Wire

Wed, Nov 02, 2011

5:00 PM

Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients - PR Newswire

Wed, Oct 05, 2011

8:16 AM

Advanced Cell Tech and Ariad Pharmaceuticals -- Highly Scrutinized But Poised for Growth - Marketwire

Thu, Aug 25, 2011

8:16 AM

Impressive Pipelines From Neoprobe and Ariad - Marketwire

Thu, Jul 28, 2011

8:16 AM

Positive FDA Trends Bode Well for Ariad and Human Genome Sciences - Marketwire

Wed, Jun 15, 2011

8:16 AM

Ariad and OXiGENE Show Encouraging Growth Potential - Marketwire

Wed, May 11, 2011

8:16 AM

Speculative Biotech Firms Battle Poor Success Rates - Marketwire

Wed, Apr 20, 2011

7:56 AM

REGENX BioSciences Licenses ARGENT(TM) Gene Regulation Technology From ARIAD Pharmaceuticals, Inc. - Marketwire

Mon, Mar 21, 2011

7:35 AM

Smaller Biotech Companies Remain Possible Takeover Targets - Marketwire

Thu, Feb 17, 2011

8:46 AM

Cell Therapeutics and Ariad Pharma Face Challenging Approval Processes - Marketwire

More News for ARIA >>

Tags for ARIAD Pharmaceuticals Inc.

Research stocks or mutual funds related to ARIAD Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to ARIA. The keywords below have been associated to ARIA by either user submission or electronic means.

advanced therapy biotech research clinical trial logistics clinical trials liability ofac regulation fda trial regulation clinical research trial biotech career clinical trials data sec regulation protein mapping fda registration lapatinib pivotal therapy system protein dls protein extract niche pharmaceutical pharmaceuticals careers clinical pharmacology pharmaceutical research and development recombinant protein annual report pancreatic cancer symptom notch signaling Biological Products tyrosine kinase inhibitor chemotherapy clinical trials uk overtime regulation anti cancer oncology treatment mitogen activated protein kinase pharmaceuticals jobs phase iii clinical trials notch pathway protein kinase a pancreatic cancer pharmaceutical executives research clinical research pi3k cancer vaccines phase 3 clinical trials intracellular signaling clinical trials manager securities regulation fda clinical trial aml history of pharmaceuticals